

**Clinical trial results:**

**A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi-Pasteur-MSDs DTPa-IPV (Tetravac), when co-administered with MMRV (Priorix Tetra) in 5 to 6-year-old healthy children.**

**Summary**

EudraCT number	2008-006124-64
Trial protocol	IT
Global end of trial date	18 November 2009

**Results information**

Result version number	v2
This version publication date	29 July 2016
First version publication date	20 February 2015
Version creation reason	• Correction of full data set Data (typos and numbers) were corrected.

**Trial information****Trial identification**

Sponsor protocol code	111815
-----------------------	--------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00871000
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000500-PIP01-08
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

### Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 June 2010
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 November 2009
Global end of trial reached?	Yes
Global end of trial date	18 November 2009
Was the trial ended prematurely?	No

Notes:

### General information about the trial

Main objective of the trial:

To demonstrate that GSK Biologicals dTpa-IPV vaccine is non-inferior to Sanofi-Pasteur-MSDs DTPa-IPV vaccine, in terms of seroprotection rates against diphtheria, tetanus and poliovirus types 1, 2 and 3, one month after vaccination.

Protection of trial subjects:

As with all injectable vaccines, appropriate medical treatment was always readily available in case of anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee remained under medical supervision for 30 minutes after vaccination

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 April 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	Italy: 303
Worldwide total number of subjects	303
EEA total number of subjects	303

Notes:

#### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	303
Adolescents (12-17 years)	0
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Boostrix Polio Group

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Boostrix Polio™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose, intramuscular administration at Day 0.

Investigational medicinal product name	Priorix Tetra™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Single dose, subcutaneously at Day 0.

<b>Arm title</b>	Tetravac Group
------------------	----------------

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Priorix Tetra™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Single dose, subcutaneously at Day 0.

Investigational medicinal product name	Tetravac™
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose, intramuscular administration at Day 0.

<b>Number of subjects in period 1</b>	Boostrix Polio Group	Tetravac Group
Started	151	152
Completed	150	152
Not completed	1	0
Consent withdrawn by subject	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Boostrix Polio Group
-----------------------	----------------------

Reporting group description: -

Reporting group title	Tetravac Group
-----------------------	----------------

Reporting group description: -

Reporting group values	Boostrix Polio Group	Tetravac Group	Total
Number of subjects	151	152	303
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
geometric mean	5	5	
standard deviation	± 0.14	± 0.14	-
Gender categorical Units: Subjects			
Female	81	68	149
Male	70	84	154

## End points

### End points reporting groups

Reporting group title	Boostrix Polio Group
Reporting group description:	-
Reporting group title	Tetravac Group
Reporting group description:	-

### Primary: Anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibody concentrations

End point title	Anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibody concentrations <sup>[1]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

At 1 Month post-vaccination

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: IU/mL				
geometric mean (confidence interval 95%)				
Anti-D	9.207 (8.057 to 10.522)	21.393 (19.165 to 23.88)		
Anti-T	12.527 (10.957 to 14.323)	11.07 (9.872 to 12.413)		

### Statistical analyses

No statistical analyses for this end point

### Primary: Anti-poliovirus types 1, 2 and 3 antibody titres

End point title	Anti-poliovirus types 1, 2 and 3 antibody titres <sup>[2]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

At 1 Month post-vaccination

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: Titers				
geometric mean (confidence interval 95%)				
Anti-Polio 1 [N=139;144]	1145.6 (978.7 to 1340.9)	948 (817.5 to 1099.4)		
Anti-Polio 2 [N=139;144]	1076.4 (908.7 to 1274.9)	1315.3 (1123.1 to 1540.3)		
Anti-Polio 3 [N=138;144]	1937.8 (1631.4 to 2301.8)	1657.3 (1385.5 to 1982.6)		

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibody concentrations above 0.1 IU/mL.

End point title	Number of subjects with anti-diphtheria (anti-D) and anti-tetanus (anti-T) antibody concentrations above 0.1 IU/mL.
End point description:	
End point type	Primary
End point timeframe:	
At 1 Month post-vaccination	

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: Subjects				
Anti-D	139	144		
Anti-T	139	144		

### Statistical analyses

<b>Statistical analysis title</b>	Seroprotection in terms of anti-D antibodies
-----------------------------------	--

---

**Statistical analysis description:**

To demonstrate that GSK Biologicals' Boostrix Polio™ vaccine is non-inferior to Sanofi-Pasteur-MSD's Tetravac™ vaccine, in terms of seroprotection rates against diphtheria, one month after vaccination.

Comparison groups	Boostrix Polio Group v Tetravac Group
Number of subjects included in analysis	283
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[3]</sup>
Parameter estimate	Difference in seroprotection rate
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.61
upper limit	2.7

**Notes:**

[3] - Non-inferiority in terms of seroprotection rates against diphtheria was demonstrated if the upper limit of the standardised asymptotic 95% confidence interval (CI) on the group difference [Tetravac Group minus Boostrix Polio Group] in the percentage of subjects with anti-diphtheria antibody concentrations  $\geq 0.1$  IU/mL was  $\leq 10\%$ .

---

<b>Statistical analysis title</b>	Seroprotection in terms of anti-T antibodies
-----------------------------------	--

**Statistical analysis description:**

To demonstrate that GSK Biologicals' Boostrix Polio™ vaccine is non-inferior to Sanofi-Pasteur-MSD's Tetravac™ vaccine, in terms of seroprotection rates against tetanus, one month after vaccination.

Comparison groups	Boostrix Polio Group v Tetravac Group
Number of subjects included in analysis	283
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[4]</sup>
Parameter estimate	Difference in seroprotection rate
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.61
upper limit	2.7

**Notes:**

[4] - Non-inferiority in terms of seroprotection rates against tetanus was demonstrated if the upper limit of the standardised asymptotic 95% confidence interval (CI) on the group difference [Tetravac Group minus Boostrix Polio Group] in the percentage of subjects with anti-tetanus antibody concentrations  $\geq 0.1$  IU/mL was  $\leq 10\%$ .

---

**Primary: Number of subjects with anti-poliovirus types 1, 2 and 3 antibody titres above 8**

End point title	Number of subjects with anti-poliovirus types 1, 2 and 3 antibody titres above 8
-----------------	--

**End point description:**

End point type	Primary
----------------	---------

**End point timeframe:**

At 1 Month post-vaccination

---

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: Subjects				
Anti-Polio 1 [N=139;144]	139	144		
Anti-Polio 2 [N=139;144]	139	144		
Anti-Polio 3 [N=138;144]	138	144		

## Statistical analyses

<b>Statistical analysis title</b>	Seroprotection in terms of anti-Polio 1 antibodies
-----------------------------------	--

Statistical analysis description:

To demonstrate that GSK Biologicals' Boostrix Polio™ vaccine is non-inferior to Sanofi-Pasteur-MSD's Tetravac™ vaccine, in terms of seroprotection rates against poliovirus type 1, one month after vaccination.

Comparison groups	Boostrix Polio Group v Tetravac Group
Number of subjects included in analysis	283
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[5]</sup>
Parameter estimate	Difference in seroprotection rate
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.61
upper limit	2.7

Notes:

[5] - Non-inferiority in terms of seroprotection rates against poliovirus type 1 was demonstrated if the upper limit of the standardised asymptotic 95% confidence interval (CI) on the group difference [Tetravac Group minus Boostrix Polio Group] in the percentage of subjects with anti-poliovirus type 1 antibody titers  $\geq 8$  was  $\leq 10\%$ .

<b>Statistical analysis title</b>	Seroprotection in terms of anti-Polio 2 antibodies
-----------------------------------	--

Statistical analysis description:

To demonstrate that GSK Biologicals' Boostrix Polio™ vaccine is non-inferior to Sanofi-Pasteur-MSD's Tetravac™ vaccine, in terms of seroprotection rates against poliovirus type 2, one month after vaccination

Comparison groups	Boostrix Polio Group v Tetravac Group
Number of subjects included in analysis	283
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Difference in seroprotection rate
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.61
upper limit	2.7

<b>Statistical analysis title</b>	Seroprotection in terms of anti-Polio 3 antibodies
Statistical analysis description: To demonstrate that GSK Biologicals' Boostrix Polio™ vaccine is non-inferior to Sanofi-Pasteur-MSD's Tetravac™ vaccine, in terms of seroprotection rates against poliovirus type 3, one month after vaccination	
Comparison groups	Boostrix Polio Group v Tetravac Group
Number of subjects included in analysis	283
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[6]</sup>
Parameter estimate	Difference in seroprotection rate
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.61
upper limit	2.72

Notes:

[6] - Non-inferiority in terms of seroprotection rates against poliovirus type 1 was demonstrated if the upper limit of the standardised asymptotic 95% confidence interval (CI) on the group difference [Tetravac Group minus Boostrix Polio Group] in the percentage of subjects with anti-poliovirus type 3 antibody titers  $\geq 8$  was  $\leq 10\%$ .

### **Secondary: Anti-pertussis toxoid (anti-PT), anti-filamentous hemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations**

End point title	Anti-pertussis toxoid (anti-PT), anti-filamentous hemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations
End point description:	
End point type	Secondary
End point timeframe: At 1 Month post-vaccination	

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PT	59.8 (52.2 to 68.5)	75.9 (65.7 to 87.7)		
Anti-FHA	556.2 (491.4 to 629.5)	613.5 (547 to 688.2)		
Anti-PRN	354.8 (280.2 to 449.4)	7.8 (6.5 to 9.2)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with anti-D and anti-T antibody concentrations $\geq 1.0$ IU/mL

End point title	Number of subjects with anti-D and anti-T antibody concentrations $\geq 1.0$ IU/mL
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 Month post-vaccination

End point values	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: Subjects				
Anti-D	138	144		
Anti-T	137	143		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seropositive subjects for anti-measles, anti-mumps, anti-rubella and anti-varicella.

End point title	Number of seropositive subjects for anti-measles, anti-mumps, anti-rubella and anti-varicella.
-----------------	--

End point description:

Seropositivity was defined as subjects with antibody concentrations:  $\geq 150$  milli-international units per milliliter (mIU/mL),  $\geq 231$  units per milliliter (U/mL),  $\geq 4$  international units per milliliter (IU/mL) and  $\geq 50$  mIU/mL for anti-measles, anti-mumps, anti-rubella and anti-varicella antibodies, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 Month post-vaccination

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	146		
Units: Subjects				
Anti- measles	139	146		
Anti-mumps	139	144		
Anti-rubella	139	145		
Anti- varicella	135	140		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-PT, anti-FHA and anti-PRN antibody concentrations

End point title	Anti-PT, anti-FHA and anti-PRN antibody concentrations
End point description:	
End point type	Secondary
End point timeframe:	
At 1 Month post-vaccination	

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PT	59.8 (52.2 to 68.5)	75.9 (65.7 to 87.7)		
Anti-FHA	556.2 (491.4 to 629.5)	613.5 (547 to 688.2)		
Anti-PRN	354.8 (280.2 to 449.4)	7.8 (6.5 to 9.2)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-measles and anti-varicella antibody concentrations.

End point title	Anti-measles and anti-varicella antibody concentrations.
End point description:	
End point type	Secondary

End point timeframe:  
At 1 Month post-vaccination

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	146		
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti- measles	2743.9 (2411.4 to 3122.2)	2863 (2534.6 to 3233.9)		
Anti- varicella	856.7 (671.8 to 1092.4)	909.9 (721 to 1148.2)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with booster responses to anti-diphtheria and anti-tetanus.

End point title	Number of subjects with booster responses to anti-diphtheria and anti-tetanus.
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 Month post-vaccination

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	137	143		
Units: Subjects				
Ant-D [N=136;143]	130	136		
Anti-T [N=137;143]	137	142		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with booster responses to anti-poliovirus types 1, 2 and 3.

End point title	Number of subjects with booster responses to anti-poliovirus types 1, 2 and 3.
End point description:	
End point type	Secondary
End point timeframe:	
At 1 Month post-vaccination	

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	144		
Units: Subjects				
Anti-Polio 1 [N=139;144]	115	112		
Anti-Polio 2 [N=139;143]	113	122		
Anti-Polio 3 [N=138;144]	126	127		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with booster responses to anti-PT, anti-FHA and anti-PRN.

End point title	Number of subjects with booster responses to anti-PT, anti-FHA and anti-PRN.
End point description:	
End point type	Secondary
End point timeframe:	
At 1 Month post-vaccination	

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	137	143		
Units: Subjects				
Anti-PT [N=137;141]	123	130		
Anti-FHA [N=136;140]	129	134		
Anti-PRN [N=137;143]	129	0		

### Statistical analyses

No statistical analyses for this end point

**Secondary: Number of seroconverted subjects for anti-measles, anti-mumps, anti-rubella and anti-varicella**

End point title Number of seroconverted subjects for anti-measles, anti-mumps, anti-rubella and anti-varicella

End point description:

End point type Secondary

End point timeframe:

At 1 Month post-vaccination

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	36	34		
Units: Subjects				
Anti-measles [N=2;1]	2	1		
Anti-mumps [N=13;13]	13	12		
Anti-rubella [N=0;0]	0	0		
Anti-varicellas [N=36;34]	35	32		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of subjects with any solicited local symptoms.**

End point title Number of subjects with any solicited local symptoms.

End point description:

End point type Secondary

End point timeframe:

During the 4-day (Days 0-3) post-vaccination period

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	151	152		
Units: Subjects				
Pain	96	96		
Redness	58	66		
Swelling	55	62		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with any solicited general symptoms.

End point title | Number of subjects with any solicited general symptoms.

End point description:

End point type | Secondary

End point timeframe:

During the 4-day (Days 0-3) post-vaccination period

End point values	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	151	152		
Units: Subjects				
Fatigue	40	36		
Gastrointestinal	23	15		
Headache	18	20		
Temperature	32	30		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with any unsolicited adverse events (AEs).

End point title | Number of subjects with any unsolicited adverse events (AEs).

End point description:

End point type | Secondary

End point timeframe:

During the 31 days (Days 0-30) post-vaccination period

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	151	152		
Units: Subjects				
Subjects with any AE(s)	23	20		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with serious adverse events (SAEs).

End point title | Number of subjects with serious adverse events (SAEs).

End point description:

End point type | Secondary

End point timeframe:

During the whole study period

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	151	152		
Units: Subjects				
Subjects with any SAE(s)	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-mumps antibody concentrations.

End point title | Anti-mumps antibody concentrations.

End point description:

End point type | Secondary

End point timeframe:

At 1 Month post-vaccination

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	146		
Units: U/mL				
geometric mean (confidence interval 95%)				
Anti-mumps	4141.3 (3590.5 to 4776.5)	3837.6 (3275.1 to 4496.7)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-rubella antibody concentrations.

End point title	Anti-rubella antibody concentrations.
End point description:	
End point type	Secondary
End point timeframe:	
At 1 Month post-vaccination	

<b>End point values</b>	Boostrix Polio Group	Tetravac Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	139	146		
Units: IU/mL				
geometric mean (confidence interval 95%)				
Anti-rubella	154.5 (141.3 to 168.9)	162.5 (145.8 to 181)		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: 4-day follow-up period after vaccination (Day 0 - Day 3); Unsolicited AEs: 31-day follow-up period after vaccination (Day 0 - Day 30); SAEs: throughout the study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	13

### Reporting groups

Reporting group title	Boostrix Group
-----------------------	----------------

Reporting group description: -

Reporting group title	Tetravac Group
-----------------------	----------------

Reporting group description: -

<b>Serious adverse events</b>	Boostrix Group	Tetravac Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 151 (0.00%)	0 / 152 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Boostrix Group	Tetravac Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	96 / 151 (63.58%)	96 / 152 (63.16%)	
General disorders and administration site conditions			
Pain			
subjects affected / exposed	96 / 151 (63.58%)	96 / 152 (63.16%)	
occurrences (all)	96	96	
Redness			
subjects affected / exposed	58 / 151 (38.41%)	66 / 152 (43.42%)	
occurrences (all)	58	66	
Swelling			
subjects affected / exposed	55 / 151 (36.42%)	62 / 152 (40.79%)	
occurrences (all)	55	62	
Fatigue			

subjects affected / exposed occurrences (all)	40 / 151 (26.49%) 40	36 / 152 (23.68%) 36
Gastrointestinal subjects affected / exposed occurrences (all)	23 / 151 (15.23%) 23	15 / 152 (9.87%) 15
Headache subjects affected / exposed occurrences (all)	18 / 151 (11.92%) 18	20 / 152 (13.16%) 20
Temperature subjects affected / exposed occurrences (all)	32 / 151 (21.19%) 32	30 / 152 (19.74%) 30

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported